Antibodies to l-type voltage gated channels and related methods

a voltage gated channel and antibody technology, applied in the field of antibodies to l-type voltage gated channels and related methods, can solve the problems of undesirable side effects, incomplete characterization of the way calcium signals are generated in immune cells, etc., to reduce the survival of nave t cells, reduce the cd3/cd28 induced t cell proliferation, and reduce the t cell receptor-induced ca2+ flux

Inactive Publication Date: 2018-01-25
PASCAL BIOSCI INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0061]In certain embodiments, the antibody or binding fragment thereof is an antibody or binding fragment thereof described herein. In certain embodiments, the hematopoietic cell is of the lymphoid lineage. In certain embodiments, the hematopoietic cell is a T cell. In certain embodiments, administering the effective amount of the antibody or antigen-binding fragment thereof decreases T cell receptor-induced Ca2+ fluxes. In certain embodiments, administering the effective amount of the antibody or antigen-binding fragment thereof reduces naïve T cell survival.
[0062]In certain embodiments, administering the effective amount of the antibody or antigen-binding fragment reduces CD3 / CD28 induced T cell proliferation. In certain embodiments, the hematopoietic cell is a B cell.

Problems solved by technology

While calcium signaling is known to play a role in immune function, the means by which calcium signals are generated in immune cells are not fully characterized.
While inhibitors to L-type voltage-gated calcium channels are presently available, these inhibitors are broadly targeted and produce undesirable side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies to l-type voltage gated channels and related methods
  • Antibodies to l-type voltage gated channels and related methods
  • Antibodies to l-type voltage gated channels and related methods

Examples

Experimental program
Comparison scheme
Effect test

example 1

Design and Generation of Antibodies Directed Against L-Type Voltage Gated Calcium Channels

[0248]Antibodies were designed to the target L-type voltage-gated calcium channel subtypes Cav1.1, Cav1.2, Cav1.3, or Cav1.4. For each channel, an amino acid sequence was selected to use as targets for use as an antigen for generating mouse monoclonal antibodies. Amino acid sequences were selected to meet several criteria. First, the amino acid sequences had to be unique to their respective channels. Second, the amino acid sequences had to reside on an exposed portion of the channel positioned outside of the cell. Third, the amino acid sequence had to be found in both the mouse and human channel. Fourth, the sequence needed to be in a region of the channel that would affect the channel's activity when bound by an antibody.

[0249]For each of the L-type voltage-gated calcium channel subtype, an amino acid sequence located in the extracellular domain of the pore loop between transmembrane segments ...

example 2

Characterization of Hybridoma Antibody Directed Against L-Type Voltage Gated Calcium Channels

[0251]ELISA experiments were preformed to characterize monoclonal antibodies generated to target the extracellular pore domain of the L-type voltage-gated calcium channels. Sixty-three antibodies of interest were tested for their abilities to bind to the peptides with amino acid sequences from Table E1 that were used to generate the antibodies. Antibody binding was tested in wells coated with BSA and all the peptides with from each L-type voltage gated calcium channel, BSA and the Cav1.1 peptide, BSA and the Cav1.2 peptide, BSA and the Cav1.3 peptide, and BSA and the Cava.4 peptide. Binding was detected with a mixture of IgG and IgM secondary antibodies, and signal was compared to negative controls. Representative results of these experiments are presented (FIG. 3). The results indicated that the antibodies could specifically bind to the target peptides. Clones were observed that bound only ...

example 3

Hybridoma Antibodies Bind to and Inhibit Growth of Jurkat T-Cells

[0256]The hybridoma clones were additionally evaluated in a flow cytometry-based binding assay using the human Jurkat leukemia cell line (Jurkat). Cell binding and growth inhibition assays were performed using standard techniques. The results are shown in Table E2 below.

TABLE E2Jurkat Binding and Growth AssaysGrowthBinding SpecificityCell bindingInhibitionClone IDCav1.1Cav1.2Cav1.3Cav1.4IsotypeJurkat1C8YesIgGYesYes1C10YesIgGYesYes1D2YesYesYesIgMYesYes1E7YesIgMYesYes1F4YesIgGYesYes2D5YesIgGYesYes5F4YesIgGYesYes5G10YesIgGNSYes6A3YesYesIgGYesYes6C6YesIgGYesNS6E1YesIgGYesYes6H7YesIgGYesYes8G1YesIgGYesYes9C3YesIgGYesYes10E11YesIgGYesYesNS—Non-specific at time of assay.

[0257]These results show that supernatants from the hybridoma clones in Table E2 were able to bind to and inhibit the growth of human Jurkat T-cells, evidencing the therapeutic potential of these antibodies in the treatment of various cancers, including hemato...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
pHaaaaaaaaaa
pHaaaaaaaaaa
pHaaaaaaaaaa
Login to view more

Abstract

Provided are antibodies, and antigen-binding fragments thereof, which specifically bind to an extracellular poor loop of an alpha 1a subunit of L-type voltage gated calcium channel, and related compositions, kits, and methods of use thereof, for instance, administration to a subject in need thereof to modify an immune response, for example, in the treatment of cancer.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority under 35 U.S.C. §119(e) to U.S. Application No. 62 / 115,823, filed Feb. 13, 2015; and U.S. Application No. 62 / 280,557, filed Jan. 19, 2016; each of which is incorporated by reference in its entirety.STATEMENT REGARDING THE SEQUENCE LISTING[0002]The Sequence Listing associated with this application is provided in text format in lieu of a paper copy, and is hereby incorporated by reference into the specification. The name of the text file containing the Sequence Listing is BIMN_005_02 WO_ST25.txt. The text file is about 177 KB, was created on Feb. 16, 2016, and is being submitted electronically via EFS-Web.BACKGROUNDTechnical Field[0003]Embodiments of the present invention include antibodies, and antigen-binding fragments thereof, which specifically bind to one or more of the L-type voltage calcium channels Cav1.4, Cav1.3, Cav1.2, and Cav1.1, and related compositions and methods of use thereof.Description of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/28C07K16/30
CPCC07K16/28C07K16/30C07K2317/34C07K2317/56C07K2317/565C07K2317/33C07K2317/76C07K14/705C07K2317/73A61P1/04A61P1/16A61P11/00A61P11/06A61P13/02A61P13/12A61P17/00A61P17/06A61P19/02A61P21/00A61P21/04A61P25/00A61P27/02A61P29/00A61P35/00A61P35/02A61P37/02A61P37/06A61P5/14A61P5/40A61P7/00A61P7/06A61P3/10
Inventor JEFFERIES, WILFRED ARTHURCHOI, KYUNG BOKSTANWOOD, SHAWNA ROSEFENNINGER, FRANZEYFORD, BRETT ALEXANDERMUNRO, LONNAPFEIFER, CHERYL GURINEGABATHULER, REINHARD
Owner PASCAL BIOSCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap